Justus M. Huelse

MERTK activation drives osimertinib resistance in EGFR-mutant non–small cell lung cancer

S. Frye, T. Owonikoko, S. Ramalingam, 2022, The Journal of clinical investigation.

MERTK in cancer therapy: Targeting the receptor tyrosine kinase in tumor cells and the immune system.

D. DeRyckere, D. Graham, Diana M Fridlyand, 2020, Pharmacology & therapeutics.

Abstract 240: MERTK inhibition induces an anti-leukemia dendritic cell - T cell axis while TYRO3 inhibition protects through a separate mechanism

S. Frye, Xiaodong Wang, H. Earp, 2022, Cancer Research.

Data-driven construction of anti-tumor agents with controlled polypharmacology.

Laura E. Herring, S. Frye, M. Miley, 2019, Journal of the American Chemical Society.

TAM family kinases as therapeutic targets at the interface of cancer and immunity

H. Earp, D. DeRyckere, D. Graham, 2023, Nature Reviews Clinical Oncology.

MERTK Inhibition as a Targeted Novel Cancer Therapy

H. Earp, Alisha Holtzhausen, Aashis Thapa, 2024, International journal of molecular sciences.